At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09939 KINTOR PHARMA-B
Not Yet Opened 01-19 15:59:49
2.390
+0.060
+2.58%
High2.400
Low2.290
Vol2.54M
Open2.330
D1 Closing2.330
Amplitude4.72%
Mkt Cap1.19B
Tradable Cap1.19B
Total Shares499.00M
T/O6.01M
T/O Rate0.51%
Tradable Shares499.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Pharma Giant with $51.5 Billion Fortune Expands Ambitions with HK$2.8 Billion Acquisition
HK Stock Movement | ALI HEALTH (00241) Rises Nearly 4%, Forms Strategic Partnership with Beijing Meiersen Pharmaceutical, Beimeijing® to Launch Exclusively Online This Tuesday
Riding the Industrial Wave with Regulatory Support: Fujian Longyan Market Regulation Bureau's Economic Development Zone Branch Boosts High-Quality Development of "3+3" Modern Industrial System
Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review
Healthcare Sector Rallies for Third Consecutive Session! Medical ETF Challenges Half-Year Moving Average, Hong Kong Stock Connect Innovative Drug ETF (520880) Surges Over 3% Against Market Trend! Multiple Brokerages Highlight Innovative Drug and Device Supply Chain
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.